Welcome to the international HTA database

Showing [16861 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2018	Health Quality Ontario (HQO)	Electronic Monitoring Systems to Assess Urinary Incontinence: A Health Technology Assessment
2018	NIHR Health Technology Assessment programme	Routine low-dose continuous or nocturnal oxygen for people with acute stroke: three-arm Stroke Oxygen Supplementation RCT
2018	NIHR Health Technology Assessment programme	AntiEpileptic drug Monitoring in PREgnancy (EMPiRE): a double-blind randomised trial on effectiveness and acceptability of monitoring strategies
2018	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Meniscal allograft transplantation for post-meniscectomy syndrome
2018	NIHR Health Technology Assessment programme	Positive behaviour support training for staff for treating challenging behaviour in people with intellectual disabilities: a cluster RCT
2018	NIHR Health Technology Assessment programme	The UK EndoVascular Aneurysm Repair (EVAR) randomised controlled trials: long-term follow-up and cost-effectiveness analysis
2018	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Stem cell treatments within surgical specialities: what is the evidence?
2018	NIHR Health Technology Assessment programme	Triple versus guideline antiplatelet therapy to prevent recurrence after acute ischaemic stroke or transient ischaemic attack: the TARDIS RCT
2018	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Leaving surgical training: some of the reasons are in surgery
2018	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Day case hernia repair: weak evidence or practice gap?
2018	NIHR Health Technology Assessment programme	Therapeutic hypothermia to reduce intracranial pressure after traumatic brain injury: the Eurotherm3235 RCT
2018	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Prostate artery embolisation: poor design and reporting impact the value of current systematic reviews
2018	NIHR Health Technology Assessment programme	Strategy of endovascular versus open repair for patients with clinical diagnosis of ruptured abdominal aortic aneurysm: the IMPROVE RCT
2018	NIHR Health Services and Delivery Research programme	NHS managers' use of nursing workforce planning and deployment technologies: a realist synthesis of implementation and impact
2018	NIHR Health Technology Assessment programme	PET-PANC: multicentre prospective diagnostic accuracy and health economic analysis study of the impact of combined modality 18fluorine-2-fluoro-2-deoxy-d-glucose positron emission tomography with computed tomography scanning in the diagnosis and management of pancreatic cancer
2018	Belgian Health Care Knowledge Centre (KCE)	MammaPrint® test for personalised management of adjuvant chemotherapy decisions in early breast cancer
2018	NIHR Health Services and Delivery Research programme	Understanding new models of integrated care in developed countries: a systematic review
2018	NIHR Health Technology Assessment programme	Surveillance following endovascular aortic aneurysm
2018	NIHR Health Services and Delivery Research programme	A staff training intervention to improve communication between people living with dementia and health-care professionals in hospital: the VOICE mixed-methods development and evaluation study
2018	Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale (CIUSSS)	[Best practices to reduce medication administration errors (MAEs) in hospital centre (HC) and long term care facilities centre (LTCF)]
2018	NIHR Health Technology Assessment programme	Adjunctive rifampicin to reduce early mortality from Staphylococcus aureus bacteraemia: the ARREST RCT
2018	NIHR Health Technology Assessment programme	(REBALANCE) REview of Behaviour And Lifestyle interventions for severe obesity: AN evidenCE synthesis
2018	NIHR Health Services and Delivery Research programme	From programme theory to logic models for multi-specialty community providers: a realist evidence synthesis
2018	Canadian Agency for Drugs and Technologies in Health (CADTH)	Optimal strategies for the diagnosis of acute pulmonary embolism: a health technology assessment
2018	NIHR Health Services and Delivery Research programme	Supporting shared decision making for older people with multiple health and social care needs: a realist synthesis to inform emerging models of health and social care
2018	Canadian Agency for Drugs and Technologies in Health (CADTH)	Composite resin versus amalgam for dental restorations: a health technology assessment
2018	Health Information and Quality Authority (HIQA)	Guidelines for evaluating the clinical effectiveness of health technologies in Ireland
2018	NIHR Health Technology Assessment programme	Treatments for dry age-related macular degeneration and Stargardt disease: a systematic review
2018	Canadian Agency for Drugs and Technologies in Health (CADTH)	Drugs for the management of rheumatoid arthritis: clinical evaluation
2018	Canadian Agency for Drugs and Technologies in Health (CADTH)	Metastatic melanoma gap analysis
2018	NIHR Health Technology Assessment programme	MRI versus laparoscopy to diagnose the main causes of chronic pelvic pain in women: a test-accuracy study and economic evaluation
2018	NIHR Health Technology Assessment programme	Adding emollient bath additives to standard eczema management for children with eczema: the BATHE RCT
2018	Canadian Agency for Drugs and Technologies in Health (CADTH)	Screening for chlamydia trachomatis and neisseria gonorrhoeae during pregnancy: a health technology assessment
2018	Canadian Agency for Drugs and Technologies in Health (CADTH)	Clinical evaluation of interventions for the management of insomnia: a review of reviews
2018	NIHR Health Technology Assessment programme	What works to increase attendance for diabetic retinopathy screening? An evidence synthesis and economic analysis
2018	NIHR Health Technology Assessment programme	A pedometer-based walking intervention in 45- to 75-year-olds, with and without practice nurse support: the PACE-UP three-arm cluster RCT
2018	Institut national d'excellence en sante et en services sociaux (INESSS)	[Optimal use guide: antibiotic prophylaxis during clean orthopedic surgery in children and adults]
2018	NIHR Health Technology Assessment programme	Screening women aged 65 years or over for abdominal aortic aneurysm: a modelling study and health economic evaluation
2018	NIHR Health Technology Assessment programme	Two interferon gamma release assays for predicting active tuberculosis: the UK PREDICT TB prognostic test study
2018	NIHR Health Technology Assessment programme	Multiparametric MRI to improve detection of prostate cancer compared with transrectal ultrasound-guided prostate biopsy alone: the PROMIS study
2018	NIHR Health Technology Assessment programme	Risk scores to guide referral decisions for people with suspected ovarian cancer in secondary care: a systematic review and cost-effectiveness analysis
2018	NIHR Health Technology Assessment programme	Computerised interpretation of the fetal heart rate during labour: a randomised controlled trial (INFANT)
2018	NIHR Health Technology Assessment programme	Therapeutic hypothermia to reduce intracranial pressure after traumatic brain injury: the Eurotherm3235 RCT
2018	NIHR Health Technology Assessment programme	Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis
2018	Canadian Agency for Drugs and Technologies in Health (CADTH)	Interventions for temporomandibular joint disorder: an overview of systematic reviews
2017	NIHR Health Technology Assessment programme	A randomised controlled study of the effectiveness of breathing retraining exercises taught by a physiotherapist either by instructional DVD or in face-to-face sessions in the management of asthma in adults
2017	National Institute for Health and Care Excellence (NICE)	Elotuzumab for previously treated multiple myeloma (terminated appraisal). NICE technology appraisal guidance 434
2017	NIHR Health Technology Assessment programme	Clinical effectiveness and cost-effectiveness of surgical options for the management of anterior and/or posterior vaginal wall prolapse: two randomised controlled trials within a comprehensive cohort study results from the PROSPECT Study
2017	National Institute for Health and Care Excellence (NICE)	Tenofovir alafenamide for treating chronic hepatitis B (terminated appraisal). NICE technology appraisal guidance 435
2017	National Institute for Health and Care Excellence (NICE)	Bevacizumab for treating EGFR mutation-positive non-small-cell lung cancer (terminated appraisal). NICE technology appraisal guidance 436
2017	NIHR Health Technology Assessment programme	A multicentre, randomised controlled trial of position during the late stages of labour in nulliparous women with an epidural: clinical effectiveness and an economic evaluation (BUMPES)
2017	National Institute for Health and Care Excellence (NICE)	Ibrutinib with bendamustine and rituximab for treating relapsed or refractory chronic lymphocytic leukaemia after systemic therapy (terminated appraisal). NICE technology appraisal guidance 437
2017	National Institute for Health and Care Excellence (NICE)	Alectinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (terminated appraisal). NICE technology appraisal guidance 438
2017	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Endobronchial valves for the treatment of emphysema bullae.
2017	National Institute for Health and Care Excellence (NICE)	Cetuximab and panitumumab for previously untreated metastatic colorectal cancer. NICE technology appraisal guidance 439
2017	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Barricaid prosthesis for partial annulus replacement
2017	National Institute for Health and Care Excellence (NICE)	Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine. NICE technology appraisal guidance 440
2017	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Endovascular arteriovenous fistula creation systems
2017	National Institute for Health and Care Excellence (NICE)	Ixekizumab for treating moderate to severe plaque psoriasis. NICE technology appraisal guidance 442
2017	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	STAR tumour ablation system
2017	National Institute for Health and Care Excellence (NICE)	Obeticholic acid for treating primary biliary cholangitis. NICE technology appraisal guidance 443
2017	NIHR Health Technology Assessment programme	Effectiveness and cost effectiveness of cognitive behaviour therapy and short-term psychoanalytic psychotherapy compared with brief psychosocial intervention in the maintenance of symptomatic remission in adolescents with unipolar major depression (IMPACT): a randomised controlled trial
2017	National Institute for Health and Care Excellence (NICE)	Afatinib for treating advanced squamous non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal). NICE technology appraisal guidance 444
2017	National Institute for Health and Care Excellence (NICE)	Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs. NICE technology appraisal guidance 445
2017	National Institute for Health and Care Excellence (NICE)	Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia. NICE technology appraisal guidance 450
2017	National Institute for Health and Care Excellence (NICE)	Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia. NICE technology appraisal guidance 451
2017	National Institute for Health and Care Excellence (NICE)	Ibrutinib for untreated chronic lymphocytic leukaemia without a 17p deletion or TP53 mutation (terminated appraisal). NICE technology appraisal guidance 452
2017	NIHR Health Technology Assessment programme	Support and Assessment for Fall Emergency Referrals (SAFER) 2: a cluster randomised trial and systematic review of clinical effectiveness and cost-effectiveness of new protocols for emergency ambulance paramedics to assess older people following a fall with referral to community-based care when appropriate
2017	National Institute for Health and Care Excellence (NICE)	Bortezomib for treating multiple myeloma after second or subsequent relapse (terminated appraisal). NICE technology appraisal guidance 453
2017	National Institute for Health and Care Excellence (NICE)	Daratumumab with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal). NICE technology appraisal guidance 454
2017	HAYES, Inc.	Dorsal root ganglion stimulation for the treatment of complex regional pain syndrome
2017	National Institute for Health and Care Excellence (NICE)	Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people. NICE technology appraisal guidance 455
2017	HAYES, Inc.	Flexitouch system (Tactile Systems Technology Inc.) for lymphedema
2017	National Institute for Health and Care Excellence (NICE)	Ustekinumab for moderately to severely active Crohn's disease after previous treatment. NICE technology appraisal guidance 456
2017	HAYES, Inc.	Glucagon-like peptide-1 receptor agonists for the treatment of obesity in women with polycystic ovary syndrome
2017	National Institute for Health and Care Excellence (NICE)	Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane. NICE technology appraisal guidance 458
2017	HAYES, Inc.	iFuse Implant System (SI-Bone Inc.) for sacroiliac joint fusion for treatment of sacroiliac joint dysfunction
2017	National Institute for Health and Care Excellence (NICE)	Adalimumab and dexamethasone for treating non-infectious uveitis. NICE technology appraisal guidance 460
2017	HAYES, Inc.	Gore cardioform septal occluder (W.L. Gore & Associates) for closure of atrial septal defects
2017	National Institute for Health and Care Excellence (NICE)	Roflumilast for treating chronic obstructive pulmonary disease. NICE technology appraisal guidance 461
2017	HAYES, Inc.	Impella 2.5 System (Abiomed Inc.) for cardiac support in patients undergoing high-risk percutaneous coronary intervention
2017	National Institute for Health and Care Excellence (NICE)	Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma. NICE technology appraisal guidance 462
2017	HAYES, Inc.	Intravenous immunoglobulin for treatment of intractable epilepsy in pediatric patients
2017	National Institute for Health and Care Excellence (NICE)	Bisphosphonates for treating osteoporosis. NICE technology appraisal guidance 464
2017	HAYES, Inc.	Ketamine infusion for treatment-resistant bipolar depression
2017	National Institute for Health and Care Excellence (NICE)	Baricitinib for moderate to severe rheumatoid arthritis. NICE technology appraisal guidance 466
2017	HAYES, Inc.	Micra transcatheter pacing system (Medtronic Inc.) for single-chamber pacemaker indications
2017	National Institute for Health and Care Excellence (NICE)	Holoclar for treating limbal stem cell deficiency after eye burns. NICE technology appraisal guidance 467
2017	NIHR Health Technology Assessment programme	The clinical effectiveness and cost-effectiveness of treat-to-target strategies in rheumatoid arthritis: a systematic review and cost-effectiveness analysis
2017	HAYES, Inc.	Ocrelizumab (Ocrevus; Genentech Inc.) for primary progressive and relapsing-remitting multiple sclerosis
2017	National Institute for Health and Care Excellence (NICE)	Methylnaltrexone bromide for treating opioid-induced constipation (terminated appraisal). NICE technology appraisal guidance 468
2017	HAYES, Inc.	Radiofrequency nerve ablation for treatment of plantar fasciitis
2017	National Institute for Health and Care Excellence (NICE)	Idelalisib with ofatumumab for treating chronic lymphocytic leukaemia (terminated appraisal). NICE technology appraisal guidance 469
2017	NIHR Public Health Research (PHR) programme	Evaluation of the impacts on health of the proposed UK industry levy on sugar sweetened beverages: developing a systems map and data platform, and collection of baseline and early impact data
2017	HAYES, Inc.	Raindrop near vision inlay (ReVision Optics Inc.) for presbyopia
2017	National Institute for Health and Care Excellence (NICE)	Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck. NICE technology appraisal guidance 473
2017	HAYES, Inc.	Teduglutide (Gattex; Shire-NPS Pharmaceuticals Inc.) to reduce parenteral support requirements in adults with short bowel syndrome
2017	National Institute for Health and Care Excellence (NICE)	Sorafenib for treating advanced hepatocellular carcinoma. NICE technology appraisal guidance 474
2017	HAYES, Inc.	Urolift system (NeoTract Inc.) for treatment of benign prostatic hyperplasia
2017	National Institute for Health and Care Excellence (NICE)	Dimethyl fumarate for treating moderate to severe plaque psoriasis. NICE technology appraisal guidance 475